BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Sauter JL, Graham RP, Larsen BT, Jenkins SM, Roden AC, Boland JM. SMARCA4-deficient thoracic sarcoma: a distinctive clinicopathological entity with undifferentiated rhabdoid morphology and aggressive behavior. Mod Pathol 2017;30:1422-32. [PMID: 28643792 DOI: 10.1038/modpathol.2017.61] [Cited by in Crossref: 93] [Cited by in F6Publishing: 97] [Article Influence: 15.5] [Reference Citation Analysis]
Number Citing Articles
1 Dermawan JK, DiNapoli SE, Sukhadia P, Mullaney KA, Gladdy R, Healey JH, Agaimy A, Cleven AH, Suurmeijer AJH, Dickson BC, Antonescu CR. Malignant undifferentiated epithelioid neoplasms with MAML2 rearrangements: A clinicopathologic study of seven cases demonstrating a heterogenous entity. Genes Chromosomes Cancer 2023;62:191-201. [PMID: 36344258 DOI: 10.1002/gcc.23102] [Reference Citation Analysis]
2 Pries K, Krüger S, Heckl S, Behrens HM, Röcken C. SMARCA4 and SMARCE1 in gastric cancer: Correlation with ARID1A, and microsatellite stability, and SMARCE1/ERBB2 co-amplification. Cancer Med 2023. [PMID: 36916408 DOI: 10.1002/cam4.5776] [Reference Citation Analysis]
3 Ma P, Cheng A-, Sun Y, Wang L. SMARCA4-deficient undifferentiated tumor presenting with fever and polyarthralgia: A case report.. [DOI: 10.21203/rs.3.rs-2605979/v1] [Reference Citation Analysis]
4 Minoshima A, Sugita S, Segawa K, Aoyama T, Ito M, Daimon F, Takenami T, Kido T, Moriya J, Nishikiori H, Hasegawa T. Usefulness of cell block examination for the cytological diagnosis of thoracic SMARCA4-deficient undifferentiated tumor: A case report. Diagn Cytopathol 2023. [PMID: 36772934 DOI: 10.1002/dc.25116] [Reference Citation Analysis]
5 Strickland AL, Maniar KP, Tanner E, Shanes E, Jennings L, Wei JJ. Borderline With Bad Behavior: An Unusual Low-grade Serous Carcinoma With Dedifferentiation From a Serous Borderline Tumor. Int J Gynecol Pathol 2023. [PMID: 36867463 DOI: 10.1097/PGP.0000000000000885] [Reference Citation Analysis]
6 Gupta S, Noona SW, Pambuccian SE, Robinson B, Martin LW, Williams E, Stelow EB, Raghavan SS. Malignant undifferentiated and rhabdoid tumors of the gastroesophageal junction and esophagus with SMARCA4 loss: a case series. Hum Pathol 2022:S0046-8177(22)00287-8. [PMID: 36549598 DOI: 10.1016/j.humpath.2022.12.008] [Reference Citation Analysis]
7 Russell-Goldman E, MacConaill L, Hanna J. Primary cutaneous SMARCA4-deficient undifferentiated malignant neoplasm: first two cases with clinicopathologic and molecular comparison to eight visceral counterparts. Mod Pathol 2022;35:1821-8. [PMID: 36085356 DOI: 10.1038/s41379-022-01152-1] [Reference Citation Analysis]
8 Huang R, Chen L, Pan C, Zhang P, Fang X, Yi J. SMARCA4-deficient dedifferentiated endometrioid carcinoma.. [DOI: 10.21203/rs.3.rs-2314735/v1] [Reference Citation Analysis]
9 Al-shbool G, Krishnan Nair H. SMARCA4-Deficient Undifferentiated Tumor: A Rare Malignancy With Distinct Clinicopathological Characteristics. Cureus 2022. [DOI: 10.7759/cureus.30708] [Reference Citation Analysis]
10 Moore DA, Le Quesne J. Bench to bedside: recent advances in lung cancer pathological research with implications for diagnostic clinical practice. Diagnostic Histopathology 2022. [DOI: 10.1016/j.mpdhp.2022.08.004] [Reference Citation Analysis]
11 Utsumi T, Taniguchi Y, Noda Y, Fukai M, Kibata K, Murakawa T. SMARCA4-deficient undifferentiated tumor that responded to chemotherapy in combination with immune checkpoint inhibitors: A case report. Thorac Cancer 2022. [PMID: 35778998 DOI: 10.1111/1759-7714.14547] [Reference Citation Analysis]
12 St Pierre R, Collings CK, Samé Guerra DD, Widmer CJ, Bolonduro O, Mashtalir N, Sankar A, Liang Y, Bi WL, Gerkes EH, Ramesh V, Qi J, Smith MJ, Meredith DM, Kadoch C. SMARCE1 deficiency generates a targetable mSWI/SNF dependency in clear cell meningioma. Nat Genet 2022;54:861-73. [PMID: 35681054 DOI: 10.1038/s41588-022-01077-0] [Reference Citation Analysis]
13 Velut Y, Decroix E, Blons H, Alifano M, Leroy K, Petitprez F, Boni A, Garinet S, Biton J, Cremer I, Wislez M, Boudou-rouquette P, Arrondeau J, Goldwasser F, Fournel L, Damotte D, Mansuet-lupo A. SMARCA4-deficient lung carcinoma is an aggressive tumor highly infiltrated by FOXP3+ cells and neutrophils. Lung Cancer 2022. [DOI: 10.1016/j.lungcan.2022.05.001] [Reference Citation Analysis]
14 Sun T, Gilani SM, Podany P, Harigopal M, Zhong M, Wang H. Cytomorphologic features of SMARCA4-deficient non-small cell lung carcinoma and correlation with immunohistochemical and molecular features. Cancer Cytopathol 2022. [PMID: 35468657 DOI: 10.1002/cncy.22581] [Reference Citation Analysis]
15 Shinno Y, Yoshida A, Masuda K, Matsumoto Y, Okuma Y, Yoshida T, Goto Y, Horinouchi H, Yamamoto N, Yatabe Y, Ohe Y. Efficacy of immune checkpoint inhibitors in SMARCA4-deficient thoracic tumor. Clinical Lung Cancer 2022. [DOI: 10.1016/j.cllc.2022.03.005] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
16 Yadav R, Sun L, Salyana M, Eric M, Gotlieb V, Wang JC. SMARCA4-Deficient Undifferentiated Tumor of Lung Mass—A Rare Tumor With the Rarer Occurrence of Brain Metastasis: A Case Report and Review of the Literature. Journal of Investigative Medicine High Impact Case Reports 2022;10:232470962210748. [DOI: 10.1177/23247096221074864] [Reference Citation Analysis]
17 Zhang L, Zhang L, Wang XI, Katz G, Tandon N, Zhao B, Lucci J, Ding J, Zhang S. The value of SOX2 in the differential diagnosis of SMARCA4 (BRG1)-deficient uterine neoplasms. Hum Pathol 2022:S0046-8177(22)00070-3. [PMID: 35331811 DOI: 10.1016/j.humpath.2022.03.009] [Reference Citation Analysis]
18 Ota T, Ishikawa T, Yasuda R, Yasuda T, Okayama T, Inoue K, Dohi O, Yoshida N, Kamada K, Uchiyama K, Takagi T, Konishi H, Naito Y, Matsuyama K, Yamaguchi T, Ootsuka K, Yoshida A, Kishimoto M, Itoh Y. The first case of SMARCA4-deficient sarcoma of stomach. Clin J Gastroenterol 2022. [PMID: 35175571 DOI: 10.1007/s12328-022-01606-8] [Reference Citation Analysis]
19 Kito Y, Kawashima K, Saigo C, Hasegawa M, Nomura S, Mikamo T, Hanamatsu Y, Matsuo Y, Takeuchi T. Thorahcic SMARCA4-deficient undifferentiated tumors with ganglioneuroma and enchondroma: implications for SLC7A11 and ARID1A expression: a case report. Diagn Pathol 2022;17. [DOI: 10.1186/s13000-022-01205-8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
20 Roden AC. Thoracic SMARCA4-deficient undifferentiated tumor-a case of an aggressive neoplasm-case report. Mediastinum 2021;5:39. [PMID: 35118344 DOI: 10.21037/med-20-15] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
21 Sørensen SG, Shrikhande A, Poulsgaard GA, Christensen MH, Bertl J, Hoffmann ER, Pedersen JS. Pan-cancer association of DNA repair deficiencies with whole-genome mutational patterns.. [DOI: 10.1101/2022.01.31.478445] [Reference Citation Analysis]
22 Ashour S, Reynolds JP, Mukhopadhyay S, McKenney JK. SMARCA4-Deficient Undifferentiated Tumor Diagnosed on Adrenal Sampling. Am J Clin Pathol 2022;157:140-5. [PMID: 34463317 DOI: 10.1093/ajcp/aqab101] [Reference Citation Analysis]
23 Muller RG, Patel N, Weidenbecher M, Abramovich CM, Ludlow D. Metastatic SMARCA4-deficient thoracosarcomatoid tumor presenting as a maxillary mass: case report and review of the literature. Otolaryngology Case Reports 2022. [DOI: 10.1016/j.xocr.2022.100397] [Reference Citation Analysis]
24 Boland JM. Unusual lung tumors-from morphology to genetics. Mod Pathol 2022;35:57-65. [PMID: 34518633 DOI: 10.1038/s41379-021-00914-7] [Reference Citation Analysis]
25 Gross JM, Ricciotti RW. Intimal Sarcoma Versus Other Spindle Cell Neoplasms. Practical Lung Pathology 2022. [DOI: 10.1007/978-3-031-14402-8_30] [Reference Citation Analysis]
26 Mao R, Liu M, Shu X, Li W, Yan W, Li X. Expanding the Immunophenotype Spectrum of SMARCA4-Deficient Non-Small Cell Lung Carcinomas: A Case Series with Neuroendocrine Markers Expression. Int J Surg Pathol 2021;:10668969211047982. [PMID: 34633874 DOI: 10.1177/10668969211047982] [Reference Citation Analysis]
27 Schwartz CJ, Pareja F, da Silva EM, Selenica P, Ross DS, Weigelt B, Brogi E, Reis-Filho JS, Wen HY. Histologic and genomic features of breast cancers with alterations affecting the SWI/SNF (SMARC) genes. Mod Pathol 2021;34:1850-9. [PMID: 34079072 DOI: 10.1038/s41379-021-00837-3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
28 Prieto TG, Baldavira CM, Machado-Rugolo J, Farhat C, Olivieri EHR, de Sá VK, da Silva ECA, Balancin ML, Ab Saber AM, Takagaki TY, Cordeiro de Lima VC, Capelozzi VL. Pulmonary Neuroendocrine Neoplasms Overexpressing Epithelial-Mesenchymal Transition Mechanical Barriers Genes Lack Immune-Suppressive Response and Present an Increased Risk of Metastasis. Front Oncol 2021;11:645623. [PMID: 34527572 DOI: 10.3389/fonc.2021.645623] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
29 Monaco SE, Brcic L, Dacic S. State-of-the-art cytology of pleural fluid, focusing on the diagnosis of mesothelioma. Cytopathology 2021. [PMID: 34467576 DOI: 10.1111/cyt.13055] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
30 Choi JH, Ro JY. Mesenchymal Tumors of the Mediastinum: An Update on Diagnostic Approach. Adv Anat Pathol 2021;28:351-81. [PMID: 34050062 DOI: 10.1097/PAP.0000000000000306] [Reference Citation Analysis]
31 Prieto TG, Machado-Rugolo J, Baldavira CM, Velosa APP, Teodoro WR, Saber AMA, Capelozzi VL. The Fibrosis-Targeted Collagen/Integrins Gene Profile Predicts Risk of Metastasis in Pulmonary Neuroendocrine Neoplasms. Front Oncol 2021;11:706141. [PMID: 34458147 DOI: 10.3389/fonc.2021.706141] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
32 Setoguchi K, Yanagi S, Gi T, Tsubouchi H, Uto K, Shigekusa T, Matsumoto N, Sato Y, Nakazato M. Transition From Distinct Types of KRAS Mutation-Harboring Multifocal Lung Adenocarcinoma to Rhabdoid Tumor: A Longitudinal Follow-Up. Am J Case Rep 2021;22:e932452. [PMID: 34432771 DOI: 10.12659/AJCR.932452] [Reference Citation Analysis]
33 Mehta A, Bansal D, Tripathi R, Jajodia A. SMARCA4/BRG1 protein-deficient thoracic tumors dictate re-examination of small biopsy reporting in non-small cell lung cancer. J Pathol Transl Med 2021. [PMID: 34147056 DOI: 10.4132/jptm.2021.05.11] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
34 Nambirajan A, Jain D. Recent updates in thoracic SMARCA4-deficient undifferentiated tumor. Semin Diagn Pathol 2021;38:83-9. [PMID: 34147303 DOI: 10.1053/j.semdp.2021.06.001] [Cited by in Crossref: 5] [Cited by in F6Publishing: 8] [Article Influence: 2.5] [Reference Citation Analysis]
35 Kudo N, Kurose A, Hara R, Takahata J, Hasui K, Sato A, Matsubara A. Rare presentation of SMARCA4-deficient thoracic tumor diagnosed with palatal tonsil biopsy. Human Pathology: Case Reports 2021;24:200508. [DOI: 10.1016/j.ehpc.2021.200508] [Reference Citation Analysis]
36 Kurokawa M, Shimizuguchi T, Ito K, Takao M, Motoi T, Taguchi A, Yasugi T, Karasawa K. Notable Response of SMARCA4-Deficient Undifferentiated Uterine Sarcoma to Palliative Radiation Therapy. Adv Radiat Oncol 2021;6:100728. [PMID: 34258477 DOI: 10.1016/j.adro.2021.100728] [Reference Citation Analysis]
37 Anžič N, Krasniqi F, Eberhardt AL, Tzankov A, Haslbauer JD. Ipilimumab and Pembrolizumab Mixed Response in a 41-Year-Old Patient with SMARCA4-Deficient Thoracic Sarcoma: An Interdisciplinary Case Study. Case Rep Oncol 2021;14:706-15. [PMID: 34177520 DOI: 10.1159/000515416] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
38 Paver E, O'Toole S, Cheng XM, Mahar A, Cooper WA. Updates in the molecular pathology of non-small cell lung cancer. Semin Diagn Pathol 2021;38:54-61. [PMID: 33985831 DOI: 10.1053/j.semdp.2021.04.001] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
39 Khanchel F, Hedhili R, Zenaidi H, Helal I, Yahmadi A, Ben Néji H, Ksontini F, Ben Brahim E, Jouini R, Chadli A. SMARCA4-deficient thoracic sarcoma revealed by metastasis to the small intestine: a diagnostic dilemma. Gen Thorac Cardiovasc Surg 2021;69:1155-8. [PMID: 33866513 DOI: 10.1007/s11748-021-01627-z] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
40 Ferrara MG, Stefani A, Simbolo M, Pilotto S, Martini M, Lococo F, Vita E, Chiappetta M, Cancellieri A, D'Argento E, Trisolini R, Rindi G, Scarpa A, Margaritora S, Milella M, Tortora G, Bria E. Large Cell Neuro-Endocrine Carcinoma of the Lung: Current Treatment Options and Potential Future Opportunities. Front Oncol 2021;11:650293. [PMID: 33937057 DOI: 10.3389/fonc.2021.650293] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
41 Horton RK, Ahadi M, Gill AJ, Said S, Chen ZE, Bakhshwin A, Nichols M, Goldblum JR, Graham RP. SMARCA4/SMARCA2-deficient Carcinoma of the Esophagus and Gastroesophageal Junction. Am J Surg Pathol 2021;45:414-20. [PMID: 33027072 DOI: 10.1097/PAS.0000000000001599] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
42 Beasley MB, Galateau-Salle F, Dacic S. Pleural mesothelioma classification update. Virchows Arch 2021;478:59-72. [PMID: 33475835 DOI: 10.1007/s00428-021-03031-7] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 8.0] [Reference Citation Analysis]
43 Sesboue C, Le Loarer F. SWI/SNF-deficient thoraco-pulmonary neoplasms. Semin Diagn Pathol 2021;38:183-94. [PMID: 33451916 DOI: 10.1053/j.semdp.2020.12.002] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
44 Gandhi JS, Alnoor F, Sadiq Q, Solares J, Gradowski JF. SMARCA4 (BRG1) and SMARCB1 (INI1) expression in TTF-1 negative neuroendocrine carcinomas including merkel cell carcinoma. Pathol Res Pract 2021;219:153341. [PMID: 33581550 DOI: 10.1016/j.prp.2021.153341] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
45 Chatzopoulos K, Boland JM. Update on genetically defined lung neoplasms: NUT carcinoma and thoracic SMARCA4-deficient undifferentiated tumors. Virchows Arch 2021;478:21-30. [PMID: 33409598 DOI: 10.1007/s00428-020-03011-3] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 4.5] [Reference Citation Analysis]
46 Mocellin S. SMARC-Deficient Thoracic Sarcoma. Soft Tissue Tumors 2021. [DOI: 10.1007/978-3-030-58710-9_230] [Reference Citation Analysis]
47 Howitt BE, Folpe AL. Update on SWI/SNF-related gynecologic mesenchymal neoplasms: SMARCA4-deficient uterine sarcoma and SMARCB1-deficient vulvar neoplasms. Genes Chromosomes Cancer 2021;60:190-209. [PMID: 33252159 DOI: 10.1002/gcc.22922] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
48 Song L, Stashek KM, Benyounes A, Davis DL, Mulligan ME, Ng VY, Kallen ME. Epithelioid sarcoma with retained INI1 (SMARCB1) expression. Histopathology 2021;78:464-6. [PMID: 32799369 DOI: 10.1111/his.14236] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
49 Rooper LM, Uddin N, Gagan J, Brosens LAA, Magliocca KR, Edgar MA, Thompson LDR, Agaimy A, Bishop JA. Recurrent Loss of SMARCA4 in Sinonasal Teratocarcinosarcoma. Am J Surg Pathol 2020;44:1331-9. [PMID: 32520761 DOI: 10.1097/PAS.0000000000001508] [Cited by in Crossref: 28] [Cited by in F6Publishing: 31] [Article Influence: 9.3] [Reference Citation Analysis]
50 Fernando TM, Piskol R, Bainer R, Sokol ES, Trabucco SE, Zhang Q, Trinh H, Maund S, Kschonsak M, Chaudhuri S, Modrusan Z, Januario T, Yauch RL. Functional characterization of SMARCA4 variants identified by targeted exome-sequencing of 131,668 cancer patients. Nat Commun 2020;11:5551. [PMID: 33144586 DOI: 10.1038/s41467-020-19402-8] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 6.7] [Reference Citation Analysis]
51 Hung YP, Redig A, Hornick JL, Sholl LM. ARID1A mutations and expression loss in non-small cell lung carcinomas: clinicopathologic and molecular analysis. Mod Pathol 2020;33:2256-68. [PMID: 32572156 DOI: 10.1038/s41379-020-0592-2] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 5.7] [Reference Citation Analysis]
52 Galliani CA, Bisceglia M, Del Giudice A, Cretì G. Desmoplastic Small Round Cell Tumor of the Kidney: Report of a Case, Literature Review, and Comprehensive Discussion of the Distinctive Morphologic, Immunohistochemical, and Molecular Features in the Differential Diagnosis of Small Round Cell Tumors Affecting the Kidney. Adv Anat Pathol 2020;27:408-21. [PMID: 32804706 DOI: 10.1097/PAP.0000000000000279] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
53 Liu J, Song L, Wang J. Primary SMARCA4-deficient undifferentiated sarcomatoid tumor of the gastroesophageal junction. Human Pathology: Case Reports 2020;22:200432. [DOI: 10.1016/j.ehpc.2020.200432] [Reference Citation Analysis]
54 Omi M, Tonooka A, Chiba T, Tanaka Y, Fusegi A, Aoki Y, Nomura H, Kanao H, Takazawa Y. Immunohistochemical markers and the clinical course of adenosarcoma: a series of seven cases. Diagn Pathol 2020;15:119. [PMID: 32972432 DOI: 10.1186/s13000-020-01036-5] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
55 Inoue M, Enomoto T, Kawamoto M, Mikami N, Kuribayashi H, Saeki N. SMARCA4-deficient lung tumour that presented with haemoptysis and progressed rapidly. Respirol Case Rep 2020;8:e00656. [PMID: 32884816 DOI: 10.1002/rcr2.656] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
56 Nambirajan A, Dutta R, Malik PS, Bubendorf L, Jain D. Cytology of SMARCA4-Deficient Thoracic Neoplasms: Comparative Analysis of SMARCA4-Deficient Non-Small Cell Lung Carcinomas and SMARCA4-Deficient Thoracic Sarcomas. Acta Cytol 2021;65:67-74. [PMID: 32854100 DOI: 10.1159/000510323] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 5.0] [Reference Citation Analysis]
57 Early CA, Wangsiricharoen S, Jones RM, VandenBussche CJ. Review of SMARCA4 (BRG1)-deficient carcinomas following a malignant pleural effusion specimen confounded by reduced claudin-4 expression. J Am Soc Cytopathol 2021;10:197-207. [PMID: 32893180 DOI: 10.1016/j.jasc.2020.08.002] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
58 Kezlarian BE, Lin O, Dogan S. SMARCB1-deficient carcinomas of the head and neck region: a cytopathologic characterization. J Am Soc Cytopathol 2020;9:494-501. [PMID: 32839151 DOI: 10.1016/j.jasc.2020.07.134] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
59 Pressey JG, Dandoy CE, Pater LE, Sroga Rios J, Sisson R, Dasgupta R, Szabo S. Small cell carcinoma of the ovary hypercalcemic type (SCCOHT): Comprehensive management of a newly diagnosed young adult. Gynecol Oncol 2020;158:538-46. [PMID: 32654763 DOI: 10.1016/j.ygyno.2020.06.160] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
60 Henon C, Blay JY, Massard C, Mir O, Bahleda R, Dumont S, Postel-Vinay S, Adam J, Soria JC, Le Cesne A. Long lasting major response to pembrolizumab in a thoracic malignant rhabdoid-like SMARCA4-deficient tumor. Ann Oncol 2019;30:1401-3. [PMID: 31114851 DOI: 10.1093/annonc/mdz160] [Cited by in Crossref: 44] [Cited by in F6Publishing: 50] [Article Influence: 14.7] [Reference Citation Analysis]
61 Schaefer IM, Hornick JL. SWI/SNF complex-deficient soft tissue neoplasms: An update. Semin Diagn Pathol 2021;38:222-31. [PMID: 32646614 DOI: 10.1053/j.semdp.2020.05.005] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 4.7] [Reference Citation Analysis]
62 Baine MK, Rekhtman N. Multiple faces of pulmonary large cell neuroendocrine carcinoma: update with a focus on practical approach to diagnosis. Transl Lung Cancer Res 2020;9:860-78. [PMID: 32676352 DOI: 10.21037/tlcr.2020.02.13] [Cited by in Crossref: 18] [Cited by in F6Publishing: 22] [Article Influence: 6.0] [Reference Citation Analysis]
63 Smith AP, Dueber JC, Allison DB. A diagnostic review of carcinomas and sarcomas of the mediastinum: making the diagnosis on fine-needle aspiration and core needle biopsy specimens. Semin Diagn Pathol 2020;37:187-98. [PMID: 32532552 DOI: 10.1053/j.semdp.2020.04.007] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
64 Chetty R, Serra S. SMARCA family of genes. J Clin Pathol 2020;73:257-60. [PMID: 32312722 DOI: 10.1136/jclinpath-2020-206451] [Cited by in Crossref: 22] [Cited by in F6Publishing: 25] [Article Influence: 7.3] [Reference Citation Analysis]
65 Iijima Y, Sakakibara R, Ishizuka M, Honda T, Shirai T, Okamoto T, Tateishi T, Sakashita H, Tamaoka M, Takemoto A, Kumaki Y, Ikeda S, Miyazaki Y. Notable response to nivolumab during the treatment of SMARCA4-deficient thoracic sarcoma: a case report. Immunotherapy 2020;12:563-9. [PMID: 32363992 DOI: 10.2217/imt-2019-0142] [Cited by in Crossref: 19] [Cited by in F6Publishing: 21] [Article Influence: 6.3] [Reference Citation Analysis]
66 Leckey BD Jr, Selim MA, Al-Rohil RN. Cutaneous metastasis of SMARCA4-deficient thoracic sarcoma: A diagnostic dilemma with therapeutic implications. J Cutan Pathol 2020;47:561-5. [PMID: 31995235 DOI: 10.1111/cup.13652] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
67 Perret R, Chalabreysse L, Watson S, Serre I, Garcia S, Forest F, Yvorel V, Pissaloux D, Thomas de Montpreville V, Masliah-Planchon J, Lantuejoul S, Brevet M, Blay JY, Coindre JM, Tirode F, Le Loarer F. SMARCA4-deficient Thoracic Sarcomas: Clinicopathologic Study of 30 Cases With an Emphasis on Their Nosology and Differential Diagnoses. Am J Surg Pathol 2019;43:455-65. [PMID: 30451731 DOI: 10.1097/PAS.0000000000001188] [Cited by in Crossref: 75] [Cited by in F6Publishing: 83] [Article Influence: 25.0] [Reference Citation Analysis]
68 Decroix E, Leroy K, Wislez M, Fournel L, Alifano M, Damotte D, Mansuet-Lupo A. [SMARCA4-deficient thoracic tumors: A new entity]. Bull Cancer 2020;107:41-7. [PMID: 31916995 DOI: 10.1016/j.bulcan.2019.12.001] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
69 Roden AC. Pathology of Thymic Carcinoma. Atlas of Thymic Pathology 2020. [DOI: 10.1007/978-981-15-3164-4_9] [Reference Citation Analysis]
70 Qian X, Zhang Y. Soft Tissue and Bone. Practical Cytopathology 2020. [DOI: 10.1007/978-3-030-24059-2_17] [Reference Citation Analysis]
71 Le Loarer F. SMARCA4-Deficient Sarcoma. Encyclopedia of Pathology 2020. [DOI: 10.1007/978-3-319-28845-1_5467-1] [Reference Citation Analysis]
72 Rekhtman N, Montecalvo J, Chang JC, Alex D, Ptashkin RN, Ai N, Sauter JL, Kezlarian B, Jungbluth A, Desmeules P, Beras A, Bishop JA, Plodkowski AJ, Gounder MM, Schoenfeld AJ, Namakydoust A, Li BT, Rudin CM, Riely GJ, Jones DR, Ladanyi M, Travis WD. SMARCA4-Deficient Thoracic Sarcomatoid Tumors Represent Primarily Smoking-Related Undifferentiated Carcinomas Rather Than Primary Thoracic Sarcomas. J Thorac Oncol 2020;15:231-47. [PMID: 31751681 DOI: 10.1016/j.jtho.2019.10.023] [Cited by in Crossref: 96] [Cited by in F6Publishing: 107] [Article Influence: 24.0] [Reference Citation Analysis]
73 Jancewicz I, Siedlecki JA, Sarnowski TJ, Sarnowska E. BRM: the core ATPase subunit of SWI/SNF chromatin-remodelling complex-a tumour suppressor or tumour-promoting factor? Epigenetics Chromatin 2019;12:68. [PMID: 31722744 DOI: 10.1186/s13072-019-0315-4] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 4.0] [Reference Citation Analysis]
74 Thway K, Folpe AL. Update on selected advances in the immunohistochemical and molecular genetic analysis of soft tissue tumors. Virchows Arch 2020;476:3-15. [PMID: 31701221 DOI: 10.1007/s00428-019-02678-7] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
75 Lin DI, Allen JM, Hecht JL, Killian JK, Ngo NT, Edgerly C, Severson EA, Ali SM, Erlich RL, Ramkissoon SH, Vergilio JA, Ross JS, Elvin JA. SMARCA4 inactivation defines a subset of undifferentiated uterine sarcomas with rhabdoid and small cell features and germline mutation association. Mod Pathol 2019;32:1675-87. [PMID: 31190001 DOI: 10.1038/s41379-019-0303-z] [Cited by in Crossref: 43] [Cited by in F6Publishing: 45] [Article Influence: 10.8] [Reference Citation Analysis]
76 Kawai T, Ogata S, Nakashima H, Urabe S, Murakami I, Hiroshima K. Clinicopathologic study of deciduoid mesothelioma using SMARCB1/INI1 immunohistochemistry and fluorescence in situ hybridization. Human Pathology 2019;93:23-9. [DOI: 10.1016/j.humpath.2019.08.016] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
77 Nambirajan A, Parshad R, Goyal A, N.k. M, Jain D. Innocuous clinical presentation of a SMARCA4-deficient thoracic sarcoma arising in a patient with chronic empyema thoracis. Pathology 2019;51:657-9. [DOI: 10.1016/j.pathol.2019.05.011] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
78 Takeda M, Tani Y, Saijo N, Shimizu S, Taniguchi Y, Otsuka K, Nakao K, Tamiya A, Okishio K, Atagi S, Ohbayashi C, Kasai T. Cytopathological Features of SMARCA4-Deficient Thoracic Sarcoma: Report of 2 Cases and Review of the Literature. Int J Surg Pathol 2020;28:109-14. [PMID: 31448657 DOI: 10.1177/1066896919870866] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
79 Stewart BD, Kaye F, Machuca T, Mehta HJ, Mohammed TL, Newsom KJ, Starostik P. SMARCA4-Deficient Thoracic Sarcoma: A Case Report and Review of Literature. Int J Surg Pathol 2020;28:102-8. [PMID: 31382829 DOI: 10.1177/1066896919865944] [Cited by in Crossref: 10] [Cited by in F6Publishing: 14] [Article Influence: 2.5] [Reference Citation Analysis]
80 Le Quang M, Ranchère-Vince D, Le Loarer F. [Pathological and molecular features of malignancies underlined by BAF complexes inactivation]. Ann Pathol 2019;39:399-413. [PMID: 31255411 DOI: 10.1016/j.annpat.2019.05.001] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
81 Mei L, Alikhan M, Mujacic I, Parilla M, Antic T. Genomic Alterations in Undifferentiated Malignant Tumors with Rhabdoid Phenotype and Loss of BRG1 Immunoexpression Identified by Fine Needle Aspirates. Acta Cytol 2019;63:438-44. [PMID: 31230044 DOI: 10.1159/000500684] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
82 Ng WK, Toe BP, Lau HY. Malignant Rhabdoid Tumor of the Mediastinum: A Case Report and Literature Review. J Clin Imaging Sci 2019;9:7. [PMID: 31448158 DOI: 10.25259/JCIS-9-7] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
83 Crombé A, Alberti N, Villard N, Pilleul F, Buy X, Le Loarer F, Kind M. Imaging features of SMARCA4-deficient thoracic sarcomas: a multi-centric study of 21 patients. Eur Radiol 2019;29:4730-41. [DOI: 10.1007/s00330-019-06017-x] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 3.3] [Reference Citation Analysis]
84 Anderson WJ, Hornick JL. Immunohistochemical correlates of recurrent genetic alterations in sarcomas. Genes Chromosomes Cancer 2019;58:111-23. [DOI: 10.1002/gcc.22700] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 3.0] [Reference Citation Analysis]
85 Yatabe Y, Dacic S, Borczuk AC, Warth A, Russell PA, Lantuejoul S, Beasley MB, Thunnissen E, Pelosi G, Rekhtman N, Bubendorf L, Mino-Kenudson M, Yoshida A, Geisinger KR, Noguchi M, Chirieac LR, Bolting J, Chung JH, Chou TY, Chen G, Poleri C, Lopez-Rios F, Papotti M, Sholl LM, Roden AC, Travis WD, Hirsch FR, Kerr KM, Tsao MS, Nicholson AG, Wistuba I, Moreira AL. Best Practices Recommendations for Diagnostic Immunohistochemistry in Lung Cancer. J Thorac Oncol 2019;14:377-407. [PMID: 30572031 DOI: 10.1016/j.jtho.2018.12.005] [Cited by in Crossref: 125] [Cited by in F6Publishing: 139] [Article Influence: 25.0] [Reference Citation Analysis]
86 Sbaraglia M, Dei Tos AP. Soft Tissue Sarcomas with Epithelioid Morphology. Soft Tissue Sarcomas 2018. [DOI: 10.1017/9781316535097.007] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
87 Hung YP, Sholl LM. Diagnostic and Predictive Immunohistochemistry for Non-Small Cell Lung Carcinomas. Adv Anat Pathol 2018;25:374-86. [PMID: 30188361 DOI: 10.1097/PAP.0000000000000206] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 2.2] [Reference Citation Analysis]
88 Matsushita M, Kuwamoto S. Cytologic Features of SMARCA4-Deficient Thoracic Sarcoma: A Case Report and Comparison with Other SWI/SNF Complex-Deficient Tumors. Acta Cytol 2018;62:456-62. [PMID: 30286456 DOI: 10.1159/000493335] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 2.4] [Reference Citation Analysis]
89 Wang Y, Chen SY, Colborne S, Lambert G, Shin CY, Santos ND, Orlando KA, Lang JD, Hendricks WPD, Bally MB, Karnezis AN, Hass R, Underhill TM, Morin GB, Trent JM, Weissman BE, Huntsman DG. Histone Deacetylase Inhibitors Synergize with Catalytic Inhibitors of EZH2 to Exhibit Antitumor Activity in Small Cell Carcinoma of the Ovary, Hypercalcemic Type. Mol Cancer Ther 2018;17:2767-79. [PMID: 30232145 DOI: 10.1158/1535-7163.MCT-18-0348] [Cited by in Crossref: 35] [Cited by in F6Publishing: 37] [Article Influence: 7.0] [Reference Citation Analysis]
90 Arnaud O, Le Loarer F, Tirode F. BAFfling pathologies: Alterations of BAF complexes in cancer. Cancer Lett 2018;419:266-79. [PMID: 29374542 DOI: 10.1016/j.canlet.2018.01.046] [Cited by in Crossref: 29] [Cited by in F6Publishing: 29] [Article Influence: 5.8] [Reference Citation Analysis]
91 Kimura N, Hasegawa M, Hiroshima K. SMARCB1/INI1/BAF47- deficient pleural malignant mesothelioma with rhabdoid features. Pathol Int 2018;68:128-32. [PMID: 29316066 DOI: 10.1111/pin.12623] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]
92 Rossi G, Ragazzi M, Cavazza A. Diagnostic Histopathology Approach. Current Clinical Pathology 2018. [DOI: 10.1007/978-3-319-90368-2_6] [Reference Citation Analysis]